Hoth Therapeutics Granted Patent From China National Intellectual Property Administration Titled 'argeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells'

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that the China National Intellectual Property Administration (CNIPA) has granted Chinese Patent, titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells."

The patent, originally filed under PCT Application No. PCT/US2019/048400 and developed by North Carolina State University, strengthens Hoth's intellectual property portfolio and provides protection in a key global market through August 27, 2039, subject to maintenance requirements.